Huimin Fan

Huimin Fan


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
HFHuimin Fan
Huimin Fan
WLWancheng Liu
Wancheng Liu
YZYanqiong Zeng
Yanqiong Zeng
YZYing Zhou
Ying Zhou
MGMeiling Gao
Meiling Gao
HYHeng Yang
Heng Yang
CDK4/6 are important regulators of cell cycle and their inhibitors have been approved as anti-cancer drugs. Here, we report a STING-dependent anti-tumor immune mechanism responsible for tumor suppression by CDK4/6 blockade. Clinical datasets show that in human tissues, CDK4 and CDK6 are over-expressed and their expressions are negatively correlated with patients’ overall survival and T cell infiltration. Deletion of Cdk4 or Cdk6 in tumor cells significantly reduce tumor growth. Mechanistically, we find that Cdk4 or Cdk6 deficiency contributes to an increased level of endogenous DNA damage, which triggers the cGAS-STING signaling pathway to activate type I interferon response. Knockout of Sting is sufficient to reverse and partially reverse the anti-tumor effect of Cdk4 and Cdk6 deficiency respectively. Therefore, our findings suggest that CDK4/6 inhibitors may enhance anti-tumor immunity through the STING-dependent type I interferon response.

1 July 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
SXShuai Xu
Shuai Xu
YZYiyao Zeng
Yiyao Zeng
XTXin Tan
Xin Tan
GZGe Zhang
Ge Zhang
AXAnchen Xu
Anchen Xu
YZYafeng Zhou
Yafeng Zhou
Purpose: Dilated cardiomyopathy (DCM) is a prevalent form of heart failure with limited therapeutic options. This study explores a novel treatment strategy involving the delivery of exosome-derived miRNA-185-5p inhibitors encapsulated in liposomes, aiming to target cardiac tissue and alleviate myocardial apoptosis and cuproptosis in DCM. Methods: The miRNA-185-5p inhibitor, identified in our previous study and extracted from exosomes, was encapsulated in liposomes functionalized with a cardiac-targeting peptide. This system was used in both in vitro and in vivo models of DCM induced by doxorubicin (DOX). We evaluated the effects of this treatment on cardiac function, apoptosis, cuproptosis, oxidative stress, and fibrosis using echocardiography, histological analysis, Western blotting, and biochemical assays. Results: In vitro experiments demonstrated that the Lipo@miR-185-5p inhibitor markedly attenuated apoptosis and cuproptosis in H9C2 cells and iPSC-derived cardiomyocytes, with a 42.6% reduction in apoptotic cell rates and over 50% downregulation of cuproptosis-related markers (both P < 0.01). In vivo, the targeted liposomal formulation significantly improved cardiac function in DOX-induced DCM mice, as evidenced by a 27.3% increase in left ventricular ejection fraction (LVEF) and a 36.5% reduction in myocardial fibrosis area (P < 0.01), along with enhanced survival. These findings underscore the therapeutic potential of this targeted delivery strategy for the treatment of dilated cardiomyopathy. Conclusion: Lipo@miR-185-5p inhibitor, utilizing exosome-derived miRNA and targeted liposomal delivery, effectively alleviates DCM-induced myocardial dysfunction. This approach represents a promising therapeutic strategy for cardiovascular diseases by targeting specific molecular mechanisms involved in heart failure.

19 February 2025 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
XWXiangyu Wang
Xiangyu Wang
XTXin Tan
Xin Tan
TZTing Zhang
Ting Zhang
SXShuai Xu
Shuai Xu
YZYiyao Zeng
Yiyao Zeng
YZYafeng Zhou
Yafeng Zhou

11 March 2025 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
XTXin Tan
Xin Tan
SXShuai Xu
Shuai Xu
YZYiyao Zeng
Yiyao Zeng
FYFengyi Yu
Fengyi Yu
ZQZhen Qin
Zhen Qin
YZYafeng Zhou
Yafeng Zhou
Ischaemic cardiomyopathy (IC) predominantly arises from prolonged deprivation of oxygen in the coronary arteries, resulting in compromised cardiac contractility or relaxation. This study investigates the role of disulfidptosis‐associated genes (DiGs) in IC. Through the analysis of datasets GSE5406 and GSE57338, we explored the association between DiGs and immune characteristics to identify crucial genes contributing to IC development. The support vector machine model emerged as the most effective, identifying key genes such as MYH9, NUBPL, MYL6, MYH10 and NCKAP1. Validation with independent datasets GSE57345, GSE48166 and single‐cell GSE145154 further supported these findings, demonstrating high predictive accuracy. Experimental validation in an IC mouse model, using Western blot, immunohistochemistry and RT‐qPCR, confirmed the altered expression of these core genes in myocardial ischaemic regions. This research not only elucidates the significance of DiGs in IC but also underscores the diagnostic potential of identified core genes.

1 December 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
AXAnchen Xu
Anchen Xu
SXShuai Xu
Shuai Xu
XTXin Tan
Xin Tan
QSQiaoyi Sun
Qiaoyi Sun
YSYahui Song
Yahui Song
YZYafeng Zhou
Yafeng Zhou
Acute myocardial infarction (AMI) remains one of the leading causes of mortality and disability worldwide, involving complex immune and inflammatory responses. Among these, macrophages play a pivotal role as key immune cells. The polarization state of macrophages determines their function in both myocardial injury and repair. In the early phase of AMI, M1 macrophages promote inflammation and facilitate the clearance of necrotic tissue by releasing pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). However, excessive or prolonged M1 polarization may contribute to myocardial fibrosis and further deterioration of cardiac function. In contrast, M2 macrophages promote tissue repair and anti-inflammatory responses in the later phase by secreting anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), thereby reducing fibrosis and facilitating myocardial remodeling. This review summarizes the dynamic changes in macrophage polarization during AMI and elaborates on their roles in myocardial injury, inflammation, and tissue repair. Furthermore, it highlights recent advances in therapeutic strategies aimed at modulating macrophage polarization to improve AMI outcomes, including mTOR inhibitors, sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and gene-editing technologies such as CRISPR/Cas9. Overall, this review underscores the importance of regulating macrophage polarization, particularly the transition from M1 to M2, as a promising therapeutic target for AMI. Modulating macrophage function may provide novel insights into enhancing myocardial repair and preventing adverse cardiac events.

1 July 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
XBXiaohong Bo
Xiaohong Bo
JFJili Fan
Jili Fan
SXShuai Xu
Shuai Xu
YZYiyao Zeng
Yiyao Zeng
AXAnchen Xu
Anchen Xu
YZYafeng Zhou
Yafeng Zhou
Background: Dilated cardiomyopathy (DCM) is a severe cardiac condition characterized by ventricular dilation and impaired systolic function, leading to heart failure and sudden death. Current treatments have limited efficacy in reversing disease progression. Recent research suggests that disulfidptosis, a novel cell death mechanism, may play a role in DCM pathogenesis, though its specific involvement remains unclear. Methods: This study utilized multiple GEO datasets to analyze the expression of 24 disulfidptosis-related genes (DiGs) in DCM patients and healthy controls. Differential expression analysis and consensus clustering were used to classify DCM patients into subgroups based on DiGs expression profiles. A predictive model was constructed using four machine learning methods, and its performance was validated with independent datasets. A ceRNA regulatory network was established, and in vivo experiments were conducted using a DCM mouse model to validate key findings. Results: Nineteen DiGs were differentially expressed between DCM and controls. Consensus clustering divided DCM patients into two subtypes with distinct immune profiles. The support vector machine (SVM) model demonstrated superior diagnostic performance (AUC = 0.983), identifying ACTN4, MYH10, TLN1, DSTN, and NCKAP1 as core predictors. In vivo validation confirmed their expression changes in myocardial tissue. Single-cell RNA-seq further revealed increased fibroblast and macrophage infiltration in DCM, along with enrichment of fibrotic and immune pathways. Quercetin and resveratrol were predicted as potential drugs targeting these core genes. Conclusion: This study demonstrates that ACTN4, MYH10, TLN1, DSTN, and NCKAP1 play significant roles in the pathogenesis of DCM, influencing immune cell infiltration and metabolic homeostasis. Quercetin and resveratrol were identified as potential therapeutic agents, offering new directions for DCM treatment.